Investigational drug · Phase 2
QLS-111
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Normal Tension Glaucoma (NTG), Glaucoma, Open-angle Glaucoma (OAG).
Phase 2Last checked: Nov 19, 2026Latest source record: Nov 2, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
3
0 still active
All registered trials
5
Any phase or sponsor naming "QLS-111"
First trial start
2024
Apr 21, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "QLS-111", any sponsor or status.
Conditions studied
As listed on its trial records.
- Normal Tension Glaucoma (NTG)
- Glaucoma
- Open-angle Glaucoma (OAG)
- Low-Tension Glaucoma, Bilateral
- Low-Tension Glaucoma, Unspecified Eye
- Non-proliferative Diabetic Retinopathy (NPDR)
- Ocular Hypertension (OHT)
Approved drugs for the same conditions: High blood pressure (hypertension) · Glaucoma · Cardiovascular and metabolic · Ophthalmology
Largest trials
Live from ClinicalTrials.gov: studies naming "QLS-111" as an intervention, largest first.
- Study of QLS-111-FDC in Open-Angle Glaucoma or Ocular HypertensionPivotal-lookingCompleted
Qlaris Bio, Inc.Industry
NCT07354516 · 64 participants · Start Mar 18, 2026 · Primary completion Jul 22, 2026
Drug: Latanoprost (0.005%) · For: OAG - Open-Angle Glaucoma; OHT - Ocular Hypertension
Sites: Largo, Florida
Qlaris Bio, Inc.Industry
NCT06016972 · 63 participants · Start Mar 5, 2024 · Primary completion Aug 20, 2024
Drug: Experimental: QLS-111 ophthalmic solution, (0.015%); Experimental: QLS-111 ophthalmic solution, (0.03%) and 1 more · For: Primary Open Angle Glaucoma (POAG); Primary Open Angle Glaucoma of Both Eyes; Primary Open-Angle Glaucoma, Unspecified Eye and 1 more
Sites: Roswell, Georgia
Qlaris Bio, Inc.Industry
NCT06030193 · 37 participants · Start Aug 13, 2025 · Primary completion Feb 23, 2026
Drug: QLS-111 ophthalmic solution (0.015%); Timolol Maleate PF 0.5% Ophthalmic Solution (Timolol) · For: Normal Tension Glaucoma (NTG); Low-Tension Glaucoma, Bilateral; Low-Tension Glaucoma, Unspecified Eye and 1 more
Sites: Seoul, South Korea
Qlaris Bio, Inc.Industry
NCT06249152 · 36 participants · Start Apr 21, 2024 · Primary completion Dec 20, 2024
Drug: QLS-111, 0.015%; QLS-111, 0.030% and 2 more · For: Open-angle Glaucoma (OAG); Ocular Hypertension (OHT); Glaucoma
Sites: Houston, Texas
Qlaris Bio, Inc.Industry
NCT07354477 · 9 participants · Start Feb 20, 2026 · Primary completion Oct 1, 2026
Drug: QLS-111 Ophthalmic Solution (0.015%); QLS-111 Ophthalmic Solution (0.075%) · For: Non-proliferative Diabetic Retinopathy (NPDR); Open-angle Glaucoma (OAG); Normal Tension Glaucoma (NTG)
Sites: Palo Alto, California
Newest research
PubMed records naming it or its code names, newest first.
- Preclinical Evaluation of Safety and Efficacy of QLS-111: A Novel Formulation of an Adenosine Triphosphate-Sensitive Potassium Channel Opener.
Wirostko BM, Roy Chowdhury U, Brandano LA, et al. · Ophthalmol Sci 2026
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.